Literature DB >> 16872553

Effects of cranberry juice on nifedipine pharmacokinetics in rats.

Yoshihiro Uesawa1, Kiminori Mohri.   

Abstract

Little information is available about drug interactions with cranberry juice (CJ). Using microsomes from the human liver and rat small intestine, this study was designed to determine whether CJ could inhibit CYP3A-mediated nifedipine (NFP) oxidase activity; it showed that CJ was a potent inhibitor of human and rat CYP3A. Preincubation with 10% vol/vol of CJ and 1 mM NADPH for 10 min resulted in significant inhibition of the NFP oxidation activity of human and rat CYP3A (18.2 and 12.6% decreases, respectively, compared with preincubation experiments without NADPH). In addition, the pharmacokinetic interaction between CJ and NFP in vivo was confirmed in rats. In comparison with a control group, the area under the concentration-time curve (AUC) of NFP was approximately 1.6-fold higher when CJ (2 mL) was injected intraduodenally 30 min before the intraduodenal administration of NFP (30 mg kg(-1)). However, the mean residence time, the volume of distribution and the elimination rate constant were not changed significantly. These data suggest that CJ component(s) inhibit the function of enteric CYP3A. In conclusion, it was found that CJ inhibits the CYP3A-mediated metabolism of NFP in both rats and humans. Furthermore, CJ alters NFP pharmacokinetics in rats.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16872553     DOI: 10.1211/jpp.58.8.0007

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  13 in total

Review 1.  Pharmacokinetic Herb-Drug Interactions: Insight into Mechanisms and Consequences.

Authors:  Enoche F Oga; Shuichi Sekine; Yoshihisa Shitara; Toshiharu Horie
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-04       Impact factor: 2.441

Review 2.  Influence of dietary substances on intestinal drug metabolism and transport.

Authors:  Christina S Won; Nicholas H Oberlies; Mary F Paine
Journal:  Curr Drug Metab       Date:  2010-11       Impact factor: 3.731

Review 3.  Pharmacokinetic Interactions between Drugs and Botanical Dietary Supplements.

Authors:  Alyssa A Sprouse; Richard B van Breemen
Journal:  Drug Metab Dispos       Date:  2015-10-05       Impact factor: 3.922

4.  Isolation and identification of intestinal CYP3A inhibitors from cranberry (Vaccinium macrocarpon) using human intestinal microsomes.

Authors:  Eunkyung Kim; Arlene Sy-Cordero; Tyler N Graf; Scott J Brantley; Mary F Paine; Nicholas H Oberlies
Journal:  Planta Med       Date:  2010-08-17       Impact factor: 3.352

Review 5.  Cranberry and urinary tract infections.

Authors:  David R P Guay
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 6.  Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport.

Authors:  Christina S Won; Nicholas H Oberlies; Mary F Paine
Journal:  Pharmacol Ther       Date:  2012-08-04       Impact factor: 12.310

7.  Effects of cranberry juice on pharmacokinetics of beta-lactam antibiotics following oral administration.

Authors:  Meng Li; Marilee A Andrew; Joanne Wang; David H Salinger; Paolo Vicini; Richard W Grady; Brian Phillips; Danny D Shen; Gail D Anderson
Journal:  Antimicrob Agents Chemother       Date:  2009-04-27       Impact factor: 5.191

8.  Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans.

Authors:  Ngoc Ngo; Zhixia Yan; Tyler N Graf; Daniel R Carrizosa; Angela D M Kashuba; E Claire Dees; Nicholas H Oberlies; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2008-12-29       Impact factor: 3.922

Review 9.  Cranberries and lower urinary tract infection prevention.

Authors:  Marcelo Hisano; Homero Bruschini; Antonio Carlos Nicodemo; Miguel Srougi
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

Review 10.  Updates on the clinical evidenced herb-warfarin interactions.

Authors:  Beikang Ge; Zhen Zhang; Zhong Zuo
Journal:  Evid Based Complement Alternat Med       Date:  2014-03-18       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.